Filing Flows › Stoke Therapeutics (STOK) › Q3 2026 › vs Q3 2025
Stoke Therapeutics (STOK) Q3 2026 vs Q3 2025 (year over year)
Stoke Therapeutics's revenue rose $623K (+6%) from $10.6M in Q3 2025 to $11.3M in Q3 2026.
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $11.3M | $10.6M | $623K | +6% |
| Other income, net | $3.7M | $3.5M | $205K | +6% |
| Net loss | $73.6M | $38.3M | $35.3M | +92% |
| Costs & expenses | $88.6M | $53.7M | $34.8M | +65% |
| Operating costs | $88.6M | $53.7M | $34.8M | +65% |
| Research & development | $59.8M | $37.7M | $22.1M | +59% |
| SG&A | $28.7M | $16.0M | $12.7M | +79% |
| Operating cash sources | $74.2M | $38.8M | $35.3M | +91% |
| Depreciation | $455K | $442K | $13K | +3% |
| Share-based compensation | $11.0M | $8.0M | $3.0M | +37% |
| Cash used in operations | $62.7M | $30.4M | $32.3M | +106% |
| Net loss absorbed | $73.6M | $38.3M | $35.3M | +92% |
| Working capital & other | $530K | $499K | $31K | +6% |
Questions
How much did Stoke Therapeutics's revenue grow year over year in Q3 2026?
Stoke Therapeutics's revenue rose $623K (+6%) from $10.6M in Q3 2025 to $11.3M in Q3 2026.